Interactions between radiotherapy and endocrine therapy in breast cancer

Endocrine-Related Cancer

Volumn 9, Issue 3, 2002, Pages 197-205

  Del Moral, R ^a   Lopez M E ^a   Nunez M I ^a   Oliver, F J ^a   Valenzuela, M T ^a   Villalobos, M ^a   Ruiz de Almodovar J M ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; DNA DAMAGE; HORMONAL THERAPY; HUMAN; IRRADIATION; MULTIMODALITY CANCER THERAPY; OUTCOMES RESEARCH; RADIATION DOSE; REVIEW; TISSUE INJURY;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DNA DAMAGE; FEMALE; HORMONE ANTAGONISTS; HUMANS; RADIOTHERAPY;

EID: 0036751091     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0090197     Document Type: Review

References (78)

1. Albain KS, Allred DC & Clark GM 1994 Breast cancer outcome and predictor of outcome: are there age differentials? Journal of the National Cancer Institute 16 35-42.
2. Allan LA, Duhig T, Read M & Fried M 2000 The p21 (WAF1/CIP1) promoter is methylated in rat-1 cells: stable restoration of p53-dependent p21 (WAF1/CIp1) expression after transfection of a genomic clone containing the p21 (WAF1/CIP1) gene. Molecular and Cellular Biology 20 1291-1294.
3. Amichetti M, Caffo O, Arcicasa M, Roncadin M, Lora O, Rignon A, Zini G, Armaroli L, Coghetto F, Zorat P, Neri S & Teodorani N 1999 Quality of life in patients with ductal carcinoma in situ of the breast treated with conservative surgery and postoperative irradiation. Breast Cancer Research and Treatment 54 109-115.
4. Amorino GP, Freeman ML & Choy H 2000 Enhancement of radiation effects in vitro by oestrogen metabolite 2-methoxyestradiol. Radiation Research 153 384-391.
5. Assikis VJ, Neven P, Jordan VC & Vergote I 1996 A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. European Journal of Cancer 32A 1464-1476.
6. Barber JBP, Burrill W, Spreadborough AR, Levine E, Warren C, Kiltie AE, Roberts SA & Scott D 2000 Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer. Radiotherapy and Oncology 55 179-186.
7. Bender CM, Zingg JM & Jones PA 1998 DNA methylation as a target for drug design. Pharmacology Research 15 175-187.
8. Bentzen SM 1997 Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. Radiotherapy and Oncology 43 121-131.
9. Bièche I, Parfait B, Moguès C, Andrieu C, Vidaud D, Spyratos F, Lidereau R & Vidau M 2001 The CGA gene as a new predictor of the response to endocrine therapy in ER-α-positive postmenopausal breast cancer patients. Oncogene 20 6955-6959.
10. Bird A 2002 DNA methylation patterns and epigenetic memory. Genes and Development 16 6-21.
11. Brahme A 2001 Individualizing cancer treatment: biological optimisation models in treatment planning and delivery. International Journal of Radiation Oncology-Biology-Physics 49 327-337.
12. Brain EGC, Misset JL & Rouëssé J 1999 Primary chemotherapy or hormone therapy for patients with breast cancer. Cancer Treatment Reviews 25 187-197.
13. Bumet NG, Johansen J, Turensson I, Nyman J & Peacock JH 1998 Describing patients' normal tissue reactions: concerning the probability of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. International Journal of Cancer 79 606-613.
14. Cameron DA, Keen JC, Dixo JM, Bellany C, Hanby A, Anderson TJ & Miller WR 2000 Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. European Journal of Cancer 36 845-851.
15. Chen H, Tritton TR, Kenny N, Absher M & Chiu JF 1996 Tamoxifen induces TGFβI activity and apoptosis of human MCF-7 breast cells in vitro. Journal of Cell Biochemistry 61 9-17.
16. Clemons M, Danson S, Hamilton T & Goss P 2001 Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treatment Reviews 27 67-82.
17. Cox JD, Stetz J& Pajak TF 1995 Toxicity criteria of the Radiation Therapy Oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology-Biology-Physics 31 1341-1346.
18. Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, Meakin JW, Shelley W & Pritchard KI 1997 An Individual patient based meta-analysis of tamoxifen versus ovarian ablation as first endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Research and Treatment 44 201-210.
19. Daidone MG, Luisi A, Veroni S, Benini E & Silvestrini R 1999 Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocrine-Related Cancer 6 61-68.
20. Daidone MG, Luisi A, Martelli G, Benini E, Veroni S, Tomasic G, De Palo G & Silvestrini R 2000 Biomarkers and outcome after tamoxifen treatment in node-positive breast cancer from eldery women. British Journal of Cancer 82 270-277.
21. Danova M, Pellicciari C, Zibera C, Mangioratti R, Gibelli N, Giordano M, Wang E, Mazzini G & Riccardi A 1993 Cell cycle kinetics effects of tamoxifen on breast cancer cells. Flow cytometric analyses of DNA content, BrdU labelling, Ki-67, PCNA and statin expression. Annals of the New York Academy of Sciences 698 174-181.
22. Diet P, Smolnikar K & Michna H 1999 The pure antioestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of Bcl-2 than tamoxifen in MCF-7 cells. Breast Cancer Research and Treatment 58 87-97.
23. Diètze EC, Caldwell E, Grupin SL, Mancini M & Seewaldt VL 2001 Tamoxifen but not 4-hydroxytamoxifen initiates apoptosis in p53(-) normal human mammary epithelial cells inducing mitochondrial depolarizartion. Journal of Biological Chemistry 276 5384-5394.
24. Dörr W & Hendry JH 2001 Consequential late effects in normal tissues. Radiotherapy and Oncology 61 223-231.
25. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, Fulton S, Hendricks CB, Kemeny M, Kornbblith AB, Louis TA, Markman M, Mayer R & Roter D 2001 National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. Journal of the National Cancer Institute 93 979-989.
26. Fabian CJ & Kimler BF 2001 New endpoint for breast cancer chemoprevention, new drugs for breast cancer prevention. Annals of the New York Academy of Sciences 952 44-59.
27. Fellowes D, Fallowfield LJ, Saunders CM & Houghton J 2001 Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for 'well tolerated' treatments? Breast Cancer Research and Treatment 66 73-81.
28. Ferlini C, Scambia G, Marone M, Distefano M, Caggini C, Ferrandina A, Isola G, Benedetti Panici P & Mancuso S 1999 Tamoxifen induces oxidative stress in oestrogen receptor negative human cancer cell lines. Breast Cancer Research and Treatment 79 257-263.
29. Freneaux P, Stoppa-Lyonnet D, Mouret E, Kambouchner M, Nicolas A, Zafrani B, Vincent-Salomon A, Fourquet A, Magdelenat H & Sastre-Garau X 2000 Low expression of bcl-2 in Brca-1-associated breast cancer. British Journal of Cancer 83 1318-1322.
30. Gazet JC, Ford HT, Gray R, McConkey C, Sutcliffe R, Quilliam J, Makinde V, Lowndes S & Coombes RC 2001 Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Annals of Oncology 12 685-691.
31. Glatstein E 2001 Personal thoughts on normal tissue tolerance, or, what the textbooks don't tell you. International Journal of Radiation Oncology-Biology-Physics 51 1185-1189.
32. Howell A, Howell SJ, Clarke R & Anderson E 2001 Where do selective oestrogen receptor modulators (SERMs) and aromatase inhibitors (Als) now fit into breast cancer treatment algorithms? Journal of Steroid Biochemistry and Molecular Biology 79 227-237.
33. Iannuzzi CM, Tencio DP, Green S, Stock RG & Rosenstein BS 2002 ATM mutations in female breast cancer patients predict for an increase in radiation induced late effects. International Journal of Radiation Oncology-Biology-Physics 52 606-613.
34. Jha MH, Avlonitis VS, Griffith CD, Lennard TW, Wilson RG, McLean LM, Dawes PD & Shirimakar J 2001 Aggressive local treatment for screen-detected DCIS results in very low rates of recurrence. European Journal of Surgical Oncology 27 454-458.
35. Jones PA & Baylin SB 2002 The fundamental role of epigenetic events in cancer. Nature Reviews Genetics 3 415-428.
36. Karpf AR, Moore BC, Ririe TO & Jones DA 2001 Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-Aza-2′-deoxycytidine. Molecular Pharmacology 59 751-757.
37. Lilling G, Hacohen H, Nordenberg J, Livnat T, Rotter V & Sidi Y 2000 Differential sensitivity of MCF-7 and LCC2 cells to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio? Cancer Letters 161 27-34.
38. Lind PARM, Wennberg B, Gagliardi G & Fomander T 2001 Pulmonary complications following different radiotherapy techniques for breast cancer, and the association to irradiated lung volume and dose. Breast Cancer Research and Treatment 68 199-210.
39. Lind PA, Marks LB, Hardenbergh PH, Clough R, Fan M, Hollis D, Hernando ML, Lucas D, Piepgrass A & Prosnitz LR 2002 Technical factors associated with radiation pneumonitis after local ± regional radiation therapy for breast cancer. International Journal of Radiation Oncology-Biology-Physics 52 137-143.
40. López E, Núñez MI, Guerrero R, del Moral R, Luna JD, Rodriguez MM, Valenzuela MT, Villalobos M & Ruiz de Almodóvar JM 2002 Breast cancer acute radiotherapy morbidity evaluated by different scoring systems. Breast Cancer Research and Treatment 73 127-134.
41. Lorimore SA, Coates PJ, Scobie GE, Milne G & Wright EG 2001 Inflammatory-type responses after exposure to ionising radiation in vivo: a mechanism for radiation-induced bystander effects? Oncogene 20 7085-7095.
42. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG & Ford HT 1998 A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Annals of Oncology 9 1179-1184.
43. Mandlekar S, Yu R, Tse-Hua T & Kong T 2000 Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathway in tamoxifene-induced apoptosis of human breast cancer cells. Cancer Research 60 5995-6000.
44. Marson LP, Kurian KM, Miller WR & Dixon JM 2001 The effect of tamoxifen on breast tumour vascularity. Breast Cancer Research and Treatment 66 9-15.
45. Nass DJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE & Graff JR 2000 Aberrant methylation of oestrogen receptor and E-cadherin 5′ CpG islands increases with malignant progresion in human breast cancer. Cancer Research 60 4346-4348.
46. Núñez MI, Villalobos M, Olea N, Valenzuela MT, Pedraza V, McMillan TJ & Ruiz de Almodóvar JM 1995 Radiation-induced DNA double-strand break rejoining in human tumour cell lines. British Journal of Cancer 71 311-316.
47. Núñez MI, Guerrero R, López E, del Moral MR, Valenzuela MT, Siles E, Villalobos M, Pedraza V, Peacock JH, Ruiz de Almodóvar JM 1998 DNA damage and prediction of radiation response in lymphocytes and epidermal skin human cells. International Journal of Cancer 76 354-361.
48. Ozsahin M, Ozsahin H, Yuquan S, Larson B, Würgler FE & Crompton NEA 1997 Rapid assay of intrinsic radiosensitivity based on apoptosis in human CD4 and CD8 T-lymphocytes. International Journal of Radiation Oncology-Biology-Physics 38 429-440.
49. Paulsen GH, Strickert T, Marthinsen AB & Lundgren S 1996 Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cell in vitro. Acta Oncologica 35 1011-1019.
50. Peacock J, Ashton A, Bliss J, Bush C, Eady J, Jackson C, Owen R, Regan J & Yamold J 2000 Cellular radiosensitivity and complication risk after curative radiotherapy. Radiotherapy and Oncology 55 173-177.
51. Pervan M, Pajonk F, Sun JR & McBride WH 2001 Molecular pathways that modify tumor radiation response. American Journal of Clinical Oncology 24 481-485.
52. Ross JS & Fletcher JA 1999 The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Seminars in Cancer Biology 9 125-138.
53. Ruiz de Almodóvar JM, Núñiez MI, McMillan TJ, Olea N, Mort C, Villalobos M, Pedraza V & Steel GG 1994 Initial radiation induced DNA damage in human tumour cell lines: a correlation with intrinsic cellular radiosensitivity. British Journal of Cancer 69 457-462.
54. Ruiz de Almodóvar C, Ruiz-Ruiz C, Muñoz-Pinedo C, Robledo G & López-Rivas A 2001 The differential sensitivity of Bcl-2-overexpresing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bcl-2 protein levels. Oncogene 20 7128-7133.
55. Ruiz de Almodóvar IM, Guirado D, Núñez MI, López MI, Guerrero R, Valenzuela MT, Villalobos M & del Moral R 2002 Individualisation of radiotherapy in breast cancer patients: possible usefulness of a DNA damage assay to measure normal cell radiosensitivity. Radiotherapy and Oncology 62 327-333.
56. Safwat A, Bentzen SM, Turesson I & Hendry JH 2002 Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. International Journal of Radiation Oncology-Biology-Physics 52 198-204.
57. Santini V, Kantarajian HM & Issa JP 2001 Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications. Annals of Internal Medicine 137 573-586.
58. Sarkaria JN, Miller EM, Parker CJ, Jordan VC & Mulcahy RT 1994 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Research and Treatment 30 159-165.
59. Siles E, Villalobos M, Valenzuela MT, Nuñez MI, Gordon A, McMillan TJ, Pedraza V & Ruiz de Almodóvar JM 1996 Relationship between p53 status and radiosensitivity in human tumour cell lines. British Journal of Cancer 73 581-588.
60. Siles E, Villalobos M, Jones L, Guerrero R, Eady JJ, Valenzuela MT, McMillan TJ & Ruiz de Almodóvar JM 1998 Apoptosis after gamma irradiation. Is it an important cell death modality? British Journal of Cancer 78 1594-1599.
61. Smith IE & Lipton L 2001 Preoperative/neoadjuvant medical therapy for early breast cancer. The Lancet Oncology 2 561-570.
62. Steel GG, McMillan TJ & Peacock JH 1989 The radiobiology of human cells and tissues. In vitro radiosensitivity: the picture has changed in the 1980s. International Journal of Radiation Biology 56 525-537.
63. Taghian AG, Assaad SI, Niemerko A, Kuter I, Younger J, Schoenthaler R, Roche M & Powell SN 2001 Risk of pnuemonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. Journal of the National Cancer Institute 93 1806-1811.
64. Tan SM, Cheung KL, Willsher PC, Blamey RW, Chan SY & Robertson JFR 2001 Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy. European Journal of Cancer 37 2331-2338.
65. Tubiana-Mathieu N, Lejeune C, Bonnier P, Genet D, Adjadj DJ, Berda JF, Muracciole X, Delaby F, Clavere P, Benyoub A, Rhein B, Juin B & Piana L 2001 Chemotherapy and concomitant irradiation in inflammatory breast cancer. Anticancer Research 21 3061-3067.
66. Tucker SL, Turesson I & Thames HD 1992 Evidence for individual differences in radiosensitivity of human skin. European Journal of Cancer 28 1783-1791.
67. Valenzuela MT, Mateos S, Ruiz de Almodóvar JM & McMillan TJ 2000 Variation in sensitizing effect of caffeine in human tumour cell lines alter γ-irradiation. Radiotherapy and Oncology 54 261-271.
68. Valenzuela MT, Guerrero R, Núñez MI, Ruiz de Almodóvar JM, Sarker M, de Murcia G & Oliver FJ 2002 PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene 21 1108-1116.
69. Vicini FA, Baglan KL, Kestin LL, Mitchell C, Chem PY, Frazier RC, Edmuinson G, Goldstein NS, Benitez P, Huang RR & Martfnez A 2001 Accelerated treatment of breast cancer. Journal of Clinical Oncology 19 1993-2001.
70. Villalobos M, Becerra D, Nuñez MI, Valenzuela MT, Siles E, Olea N, Pedraza V & Ruiz de Almodóvar JM 1996 Radiosensitivity of human breast cancer cell lines of different hormonal responsiveness. Modulatory effects of oestradiol. International Journal of Radiation Biology 70 161-169.
71. Wazer DE, Joyce M, Solares G & Schmith-Ulrich R 1991 Proliferative inhibition of human breast carcinoma cells by high concentration estradiol does not alter radiosensitivity. Breast Cancer Research and Treatment 18 141-148.
72. Withers HR 1992 Biologic basis of radiation therapy. In Principles and Practice of Radiation Oncology, edn 2, pp 64-96. Eds CA Perez & WB Luther. Philadelphia: Lippincott.
73. West CML, Davidson SE, Elyan SAG, Valentine H, Roberts SA, Swindel R & Hunter RD 2001 Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. International Journal of Radiation Oncology, Biology, Physics 51 10-15.
74. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG 8,: & Davidson NE 2001 Synergistic activation of functional oestrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Research 61 7025-7029.
75. 125I-oestrogen decay in non-oestrogen receptor expressing human breast cancer cells, MDA-231 and oestrogen receptor expressing MCF-7 cells. International Journal of Radiation Oncology. Biology, Physics 77 955-962.
76. Zambetti M, Oriana S, Quattrone P, Verderio P, Terenziani M, Zucali R, Valagusa P & Bonadonna G 1999 Combined sequential approach in locally advanced breast cancer Annals of Oncology 10 305-310.
77. Zavagno G, Meggiolaro F, Pluchinotta A, Bozza F, Favretti F, Marconato R, Geraci G, Nistri R, Fontana P, Sorrentino P, Lumachi F, Toniato A, Rossi CR & Lise M 2000 Influence of age and menopausal status on pathologic and biologic features of breast cancer. The Breast 9 320-328.
78. Ziyaie D, Hupp TR & Thompson AM 2000 p53 and breast cancer. The Breast 9 239-246.